Cardiomyopathies market set to reach $5.2 billion by 2031
The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), and Japan) at a compound annual growth rate (CAGR) of 12.4%.
Data and analytics company GlobalData notes that growth in the USA, 5EU and Japan will largely be driven by late-stage pipeline products.
According to GlobalData’s report, ‘ Cardiomyopathies Market Size and Trend Report, 2021-2031’, cardiomyopathies are most often managed with generic drugs such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze